Piramal Pharma Forecast | Price, Price Target & Analyst Assessment

Piramal Pharma

NSEI:PPLPHARMA

Rp 141,07

Rp0,00 (0,00%)

141,07 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Piramal Pharma Stock Value

The current analyst recommendation for NSEI:PPLPHARMA is: Buy.

Buy

Piramal Pharma Company Info

EPS Growth 5Y

-40,26%

Market Cap

Rp187,32 B

Long-Term Debt

Rp32,14 B

Quarterly earnings

05/14/2026

Dividend

Rp0,14

Dividend Yield

0,10%

Founded

2020

Industry

Health Care

Country

India

Website

Piramal Pharma

ISIN Number

INE0DK501011

Website

http://www.piramalpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp205,00

45.32%

Last Update: 03/28/2026

Analysts: 10

Highest Price Target Rp285,00

Average Price Target Rp205,00

Lowest Price Target Rp160,00

In the last five quarters, Piramal Pharma’s Price Target has risen from Rp175,69 to Rp182,00 - a 3,59% increase. Eight analysts predict that Piramal Pharma’s share price will increase in the coming year, reaching Rp205,00. This would represent an increase of 45,32%.

Top growth stocks in the health care sector (5Y.)

What does Piramal Pharma do?

Piramal Pharma Limited operates as a pharmaceutical company that engages in the manufacture and sale of pharmaceuticals, medicinal, chemical, and botanical products. Business Segments The company operates through Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and India Consumer Healthcare (ICH) segments. Piramal Pharma Solutions (PPS) This segment serves as an Integrated Contract Development and Manufacturing Organization (CDMO). PPS specializes in the development and manufactu...

Piramal Pharma Limited operates as a pharmaceutical company that engages in the manufacture and sale of pharmaceuticals, medicinal, chemical, and botanical products.

Business Segments

The company operates through Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and India Consumer Healthcare (ICH) segments.

Piramal Pharma Solutions (PPS)

This segment serves as an Integrated Contract Development and Manufacturing Organization (CDMO). PPS specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and formulations. This segment holds a reputation for quality and timely delivery, catering to both regulated and emerging markets.

Piramal Critical Care (PCC)

This segment focuses on Complex Hospital Generics (CHG). This segment offers a variety of products, such as inhalation anaesthesia, injectable anaesthesia, pain management solutions, and intrathecal therapy products. PCC plays a crucial role in supplying critical care medications to hospitals, emphasizing reliability and safety.

India Consumer Healthcare (ICH)

This segment markets over the counter (OTC) products, which include well-known brands, such as Lacto Calamine, Little’s Expert Baby Care, Tetmosol, and I-range. This segment addresses the needs of everyday consumers, offering products that enhance health and wellness.

The diversity in business segments enables company to cater to a vast customer base, including distributors, pharmacy chains, hospitals, government institutions, retail consumers, and other pharmaceutical companies. The company’s extensive capabilities in manufacturing and scale allow it to meet varying consumer demands effectively.

Business Strategy

The company's business strategy is centered on innovation and excellence in service delivery. The company seeks to create a sustainable competitive advantage by investing in research and development, as well as enhancing its production capabilities. Partnerships and alliances are key elements that underpin the company’s strategy, enabling enhanced access to markets and innovation.

Furthermore, customer-centricity remains a core focus in the company’s strategy. By understanding customer needs and preferences, the company is positioned to optimize its product offerings and develop tailored solutions that address specific market requirements.

Products and Services

The company offers a comprehensive range of products and services across different segments:

Pharmaceuticals: The core product line includes APIs and formulations manufactured under stringent quality standards. This includes generic and proprietary medications aimed at treating a range of health conditions.

Hospital Generics: The product offerings encompass injectable and inhalation anaesthetics critical in hospital settings. Advanced manufacturing techniques ensure that the products meet the highest standards of safety and efficacy.

Consumer Healthcare: This segment features a variety of well-established OTC products for consumers. Each product is formulated to enhance health and well-being, resonating with the consumer’s needs for quality and effectiveness.

Contract Development and Manufacturing Services: As a CDMO, the company provides tailored services for other pharmaceutical firms looking to outsource their manufacturing and development processes. This service is characterized by flexibility, speed, and adherence to regulatory standards.

The company utilizes cutting-edge technology and exemplary practices to maintain product quality and safety along the value chain, ensuring consistent delivery of high-quality health solutions.

Geographical Markets

The company has established a significant global presence, serving markets across numerous geographical regions. The company operates in approximately 100 countries, providing opportunities for expansion and growth.

Customers

The company serves a diverse portfolio of clients across various sectors. The company’s customer base includes distributors and pharmacy chains that play a crucial role in distributing products to retail outlets; Hospitals, which rely on reliable access to critical care medications and generics for patient care; government institutions that procure pharmaceuticals and healthcare products for public health initiatives; and retail consumers who utilize OTC products made available through various channels.

The company’s extensive reach ensures it is able to meet the broadband spectrum of customer needs effectively.

Sales and Marketing

The company employs a multi-faceted approach to sales and marketing. The company utilizes direct and indirect sales channels to reach consumers and healthcare providers. The company’s sales strategy emphasizes building long-term relationships with healthcare professionals and institutions, which facilitates trust and recognition in the marketplace.

Marketing initiatives are supplemented with digital tools and platforms to enhance brand visibility and engage with customers effectively. The company participates in trade shows and healthcare conferences to showcase innovations and connect with industry stakeholders.

Distribution channels are diversified, encompassing direct sales through internal teams, partnerships with distributors, and online platforms that increase product accessibility to consumers.

History

Piramal Pharma Limited was incorporated in 2020.

Piramal Pharma Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Services:** approx. 60% **Consumer Healthcare:** approx. 25% **Specialty Products:** approx. 15% **TOP 3 Markets:** 1. **India:** approx. 40% 2. **USA:** approx. 30% 3. **Europe:** approx. 20% Piramal Pharma Limited generates the majority of its revenue from pharmaceu...

At which locations are the company’s products manufactured?

**Production Sites of Piramal Pharma Limited:** Piramal Pharma Limited operates multiple production facilities worldwide. The main production sites are located in: 1. **India:** Several facilities, including in Mumbai, Hyderabad, and Ahmedabad. 2. **North America:** Production sites in the USA and...

What strategy does Piramal Pharma pursue for future growth?

**Revenue Growth:** Estimated at 10-12% annually (based on the latest available data and industry comparisons) **Focus on Research and Development:** Increase R&D spending by approximately 15% annually Piramal Pharma Limited pursues a growth strategy that heavily emphasizes research and develo...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients, packaging materials **Main importing countries:** China, Germany, USA Piramal Pharma Limited imports a variety of raw materials necessary for the production of their pharmaceutical products. Among the most important raw...

How strong is the company’s competitive advantage?

**Market Share:** 5% (estimated for 2026) **R&D Expenses:** 8% of revenue (2025) **EBITDA Margin:** 18% (2025) Piramal Pharma Limited has a moderate competitive advantage in the pharmaceutical industry, supported by its specialized product range and strategic partnerships. The company conti...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2026) **Insider Buys/Sells:** No significant changes reported (2026) The institutional investor share in Piramal Pharma Limited is estimated to be around 45%. This figure reflects the confidence of institutional investors in the company and may...

What percentage market share does Piramal Pharma have?

**Market share of Piramal Pharma Limited:** Estimate: 3-5% (2026) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8-10% 2. **Dr. Reddy's Laboratories Ltd.:** 7-9% 3. **Cipla Ltd.:** 6-8% 4. **Aurobindo Pharma Ltd.:** 5-7% 5. **Lupin Ltd.:** 4-6% 6. **Pir...

Is Piramal Pharma stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **EBITDA Margin:** 18% (2025) **R&D Expenses:** 6% of revenue (2025) Piramal Pharma Limited recorded a revenue growth of 8.5% in 2025, attributed to robust demand in its core segments and successful market expansions. The EBITDA margin of 18% indicates that the c...

Does Piramal Pharma pay a dividend – and how reliable is the payout?

**Dividend Yield:** Estimate 2.5% (2026) Piramal Pharma Limited has distributed dividends in the past, but the exact numbers for 2026 are not available. Based on historical data and general practices in the pharmaceutical sector, a dividend yield of around 2.5% could be realistic. The reliability...

New support ticket

Explore

Piramal Pharma Stock Value

Piramal Pharma Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Piramal Pharma do?

Piramal Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Piramal Pharma Stock Value

Piramal Pharma Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Piramal Pharma do?

Piramal Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.